BioSpace News Archive

Studies to evaluate liver and pancreatic cancers with SD-101, an investigational TLR9 agonist, in combination with checkpoint inhibition immunotherapy

Bolt Biotherapeutics announced that Randall C. Schatzman, Ph.D., Chief Executive Officer, will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 10:15 AM ET.

Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that Manny Simons, Ph.D., founder, president, and CEO of Akouos, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14 at 4:30 p.m. ET.

Value of KidneyIntelX Testing Demonstrated by Data from 401 Physician Study Presented at National Kidney Foundation 2021 Spring Clinical Meetings

Abby is the next generation chemiluminescence Western protein analyzer and Stellar modules set the standard for fluorescence sensitivity

Ionis Pharmaceuticals announces pivotal patient trial of antisense therapy following aggressive joint research effort led by the non-profits The ALS Association and Project ALS.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $550.0 million aggregate principal amount of 0% Convertible Senior Notes due 2026

Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII) announced today that it has completed a minority investment and entered into an acquisition option agreement with CarePICS, LLC (CarePICS ® ), a telehealth company offering a virtual care platform designed to improve the outcomes of patients suffering from peripheral artery disease (PAD), critical limb ischemia (CLI) and lower extremity wounds.

Trial did not meet the co-primary efficacy endpoints; no new safety signals identified

BeiGene Launches BRUKINSA ® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia BRUKINSA is now commercially available in Canada following approval in March. Canadian patients now have access to the myBeiGene ® patient support program.